The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | 7-year follow-up of RESONATE-2 trial for CLL/SLL
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, gives an update on the Phase III RESONATE-2 trial, discussing data from up to 7 years of follow-up. This trial investigated using ibrutinib versus chlorambucil in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The rate of progression-free survival after 6.5 years was 61% in patients treated with ibrutinib and 9% in patients treated with chlorambucil. The rate of overall survival after 6.5 years among patients treated with ibrutinib was 78%. The data indicates that ibrutinib is an effective and well-tolerated treatment option for patients with CLL or SLL. Dr Ghia highlights findings from subgroup analysis and comments on the safety findings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
